EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Liquid Biopsy Meets Assembloids: PSA/miRNA/IL in Prostate Cancer

Joanna Bialek iD, Theresa Rohr, Paolo Fornara, Karl Weigand, Georgios Gakis, Gerit Theil iD

Cancers · 15.07.2026 · 18 (14) · 2274

DOI: 10.3390/cancers18142274 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 15.07.2026. Verfasst von Joanna Bialek und 5 weiteren Autor:innen. Beteiligte Einrichtung: Medical Faculty of Martin Luther University Halle-Wittenberg, University Clinic and Outpatient Clinic for Urology, 06120 Halle (Saale), Germany. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical examination of prostate disorders includes PSA testing, which is organ- but not cancer-specific. MicroRNAs (miRs) contribute to pathological and physiological conditions of many organs. This study investigated PSA, miRs, and interleukins (ILs) and validated findings using prostate cell line-based assembloids.

Methods

During a 10-year PSA-based observational study, the expression of miRs (-16, -141, -221, -222, and -375), IL-6, and IL-8 was analyzed in an exploratory cohort using digital PCR and chemiluminescent immunoassays. Prostate assembloids composed of epithelial and fibroblastic cell lines combined with healthy, BPH, or PCa cells were used for in vitro validation. Statistical analyses were performed using Kruskal–Wallis or ANOVA tests and ROC curve analysis.

Results

We diagnosed PCa in 19 and BPH in 77 men. PSA and IL-8 levels significantly distinguished PCa from BPH and healthy controls. Serum miR-141 and -222 were reduced in BPH and slightly lower in the PCa group than in the healthy controls. PCa assembloids showed reduced miR-141 and elevated IL-6 and IL-8. ROC analysis showed that miR-141 and miR-222 discriminated BPH from healthy controls (AUCs 0.846 and 0.807), comparable to PSA, whereas PSA performed best for PCa.

Conclusions

Our data suggest that miR-141 and miR-222 may complement PSA in prostate disorder diagnostics, showing comparable performance for BPH vs. healthy controls, while PSA performed best for PCa detection. However, given the limited sample size and the lack of external validation, our study should be considered exploratory and requires validation in larger, independent cohorts.

Schlagwörter

Stichwörter der Autor:innen

LBPCaPSAassembloidsliquid biopsymiRmicroRNAprostateprostate-specific antigen

Autor:innen und Institutionen

  • Medical Faculty of Martin Luther University Halle-Wittenberg, University Clinic and Outpatient Clinic for Urology, 06120 Halle (Saale), Germany.
  • Department of Urology, University Medicine Rostock, 18057 Rostock, Germany.

ORCID-Profile: Joanna Bialek, Gerit Theil

Zitieren

APA

Bialek, J., Rohr, T., Fornara, P., Weigand, K., Gakis, G., & Theil, G. (2026). Liquid Biopsy Meets Assembloids: PSA/miRNA/IL in Prostate Cancer. Cancers, 18(14), 2274. https://doi.org/10.3390/cancers18142274

Vancouver

Bialek J, Rohr T, Fornara P, Weigand K, Gakis G, Theil G. Liquid Biopsy Meets Assembloids: PSA/miRNA/IL in Prostate Cancer. Cancers. 2026;18(14):2274. doi:10.3390/cancers18142274

BibTeX
@article{Bialek2026,
  author = {Bialek, Joanna and Rohr, Theresa and Fornara, Paolo and Weigand, Karl and Gakis, Georgios and Theil, Gerit},
  title = {Liquid Biopsy Meets Assembloids: PSA/miRNA/IL in Prostate Cancer},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {14},
  pages = {2274},
  doi = {10.3390/cancers18142274}
}
Kostenlos starten →